Business is picking up in the pharmaceutical industry.
The American laboratory Abbvie announced at the end of last week that it would spend $ 2 billion to get its hands on an anticancer drug from a Chinese biotech, I-Mab, listed on the Nasdaq.
This is an immunotherapy treatment that Abbvie will develop and market outside of China.
This operation is a continuation of another partnership, established last June in oncology, with the Danish biotech Genmab.
In mid-August, Sanofi bought the American biotech Principia Biopharma for 3.7 billion dollars.
An acquisition that allows him to strengthen in autoimmune diseases and allergies.
Two days later, Johnson & Johnson was spending almost twice as much ($ 6.5 billion) to afford Momenta Pharmaceuticals, signing the industry's biggest deal of the year to date.
This Cambridge (Massachusetts) -based biotech also specializes in autoimmune diseases.
This article is for subscribers only.
You have 73% left to discover.
Subscribe: 1 € the first month
Can be canceled at any time
Enter your email
Already subscribed?
Log in